Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

4
Top Research Reports for AT&T, Home Depot & Cisco

2018-07-17 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AT&T (T), Home Depot (HD) and Cisco (CSCO). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
HD CBSH LMT CBSHP BSX NYLD VEEV TWX TWC NYLD.A CBCB BYD

5
What's in the Cards for Zimmer Biomet (ZBH) in Q2 Earnings?

2018-07-17 zacks
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) is set to report second-quarter 2018 results on Jul 27, before the markets open.
ALGN BSX BAX ZBH

3
LZAGY vs. BSX: Which Stock Is the Better Value Option?

2018-07-17 zacks
Investors interested in stocks from the Medical - Products sector have probably already heard of Lonza Group Ag (LZAGY - Free Report) and Boston Scientific (BSX - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
LZAGY BSX O6Z LZAGF

25
Boston Scientific Is A Solid Buy Opportunity In 2018

2018-07-17 seekingalpha
Endoscopy, Urology, and Pelvic Health segments are proving to be major growth drivers for Boston Scientific in 2018.
ABT BSX JNJ SYK ABT EW MDT GI

3
AngioDynamics (ANGO) Q4 Performance Dull, Competition Rife

2018-07-17 zacks
On Jul 16, we issued an updated research report on AngioDynamics (ANGO - Free Report) . It is currently one of the underperforming stocks in the MedTech space. A soft fiscal fourth-quarter performance and high debt levels raise concern.
ANGO BSX VEEV GHDX SGH

9
Can Strategic Alliances Aid LabCorp's (LH) Q2 Earnings?

2018-07-16 zacks
Laboratory Corporation of America Holdings (LH - Free Report) also known as LabCorp, is slated to report second-quarter 2018 results on Jul 25 before the market opens. Last reported quarter, the company delivered a positive earnings surprise of 5.30% with its average trailing four-quarter beat being 3.85%.
ALGN BSX NTRS GTT NTRSP BAX

12
Thermo Fisher (TMO) to Report Q2 Earnings: What's in Store?

2018-07-16 zacks
Thermo Fisher Scientific Inc. (TMO - Free Report) is slated to report second-quarter 2018 results before the market opens on Jul 25. Last reported quarter, the company delivered a positive earnings surprise of 3.31%. Moreover, Thermo Fisher surpassed estimates in all the trailing four quarters with an average beat of 3.16%.
ALGN BSX NTRS GTT TMO NTRSP BAX

10
Can Rhythm and Neuro Aid Boston Scientific (BSX) Q2 Earnings?

2018-07-16 zacks
Boston Scientific Corporation (BSX - Free Report) recently renamed the Rhythm Management business as Rhythm and Neuro, which now includes Cardiac Rhythm Management (CRM), Electrophysiology (EP) and Neuromodulation (previously part of the MedSurg segment). This segment emerged as the second largest contributor to Boston Scientific’s top line on solid sub-segmental performance in the last reported quarter.
ALGN POOL BSX GTT SYK GHDX

7
Boston Scientific (BSX) Q2 Earnings: Is a Beat in Store?

2018-07-13 zacks
Boston Scientific Corporation (BSX - Free Report) is scheduled to report second-quarter 2018 results before the opening bell on Jul 25.
RMD BSX SYK RMD HSIC

3
High Expectations Could Be Teleflex's Most Serious Challenge

2018-07-11 seekingalpha
Through mix improvements and savvy acquisitions, Teleflex has laid the groundwork for revenue growth to accelerate into the 6%-7% range on a core basis.
SMIN BSX SMGZY TFX SMGKF

7
Why You Should Add Boston Scientific (BSX) to Your Portfolio

2018-07-10 zacks
Boston Scientific Corporation (BSX - Free Report) has been gaining investor confidence on consistently positive results. Over the past six months, the company’s share price has outperformed its industry. The stock has rallied 23.2% compared with the industry's 5.2% rise. Also, the company has surpassed the S&P 500’s breakeven share performance.
ALGN BSX SYK GHDX

3
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?

2018-07-10 zacks
Investors focused on the Medical space have likely heard of Boston Scientific (BSX - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
BSX

10
Will Core Segmental Growth Aid Stryker (SYK) in Q2 Earnings?

2018-07-09 zacks
Stryker Corporation’s (SYK - Free Report) second-quarter 2018 results are scheduled for release on Jul 24, after market close. The company’s acquisition-driven strategy is expected to boost growth by expanding product offerings across all segments.
BSX SYK MCK ENTL

3
Bovie Medical sees Q2 revenue $11.2 mln-$11.5 mln; FactSet consensus $10.1 mln

2018-07-09 marketwatch
Bovie Medical Corporation Announces Agreement to Sell “Core” Business Segment to Symmetry Surgical, Inc. for Total Cash Consideration of $97 million
BSX BVX SSRG

85
XON / Intrexon Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-07 fintel.io
Intrexon Corp. (NYSE:XON) has 183 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 111,162,559 shares. Largest shareholders include Third Security, LLC, Iridian Asset Management Llc/ct, Vanguard Group Inc, FMR LLC / Fidelity, Lmm Llc, State Street Corp, First Trust Advisors Lp, Morgan Stanley, BlackRock Inc.
STT STT.PRC XON STT.PRE STT.PRD STT.PRG MS.PRE VRX MS.PRF MS.PRG ISRG MS.PRA PGNX BLK MS.PRI BSX MS.PRK ICUI MS SLXP MZOR

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to BSX / Boston Scientific Corp. on message board site Silicon Investor.

belo sun bsx on the tsxv: Boston Scientific (BSX) Any Comments???
Boston Scientific Borealis Tech (BSXC) CANOTC is either...
IBS Interactive, Inc. (IBSX) Black Sea Energy (BSX)
CUSIP: 101137107